A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
The main aims of this study is to test for any side effects from modakafusp alfa in
combination therapy and to determine the recommended dose of combination therapy with
modakafusp. The dose of modakafusp alfa will be increased a little at a time until the
highest...
Age: 18 years - 66+
Gender: All
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and
efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).
Age: 18 years - 66+
Gender: All
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of cilta-cel
out-of-specification (OOS).
Age: 18 years - 66+
Gender: All
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination
with talquetamab or teclistamab, and to characterize the safety and tolerability of
talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Age: 18 years - 66+
Gender: All
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
The purpose of this study is to collect long-term follow-up data on delayed adverse events
after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and
understand the long-term safety profile of cilta-cel.
Age: 18 years - 66+
Gender: All
A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a first-in-human (FIH), 2-part, open-label, multi-center, Phase 1/1b safety,
tolerability, pharmacokinetics (PK), and efficacy study of oral SETD2 inhibitor, EZM0414, in
subjects with relapsed/refractory (R/R) Multiple Myeloma (MM) and R/R Diffuse Large B-Ce...
Age: 18 years - 66+
Gender: All
MM CAR-T to Upgrade Response BMTCTN1902
This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell
Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post
autologous hematopoietic cell transplant (HCT) responses among patients with multiple...
Age: 18 - 71 years
Gender: All
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic
potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
Age: 18 years - 66+
Gender: All
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to
determine the safety, tolerability, efficacy, PK of bb2121 in combination with other
therapies in adult subjects with R/RMM.
The following combinations will be
- Arm A wi...
Age: 18 years - 66+
Gender: All
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to
determine the safety, tolerability, efficacy, PK of bb2121 in combination with other
therapies in adult subjects with R/RMM.
The following combinations will be
- Arm A wi...
Age: 18 years - 66+
Gender: All
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in
participants with relapsed and/or refractory multiple myeloma (R/R MM).
Age: 18 years - 66+
Gender: All
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy of talquetamab in participants with
relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Age: 18 years - 66+
Gender: All
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase
2 dose (RP2D).
Age: 18 years - 66+
Gender: All
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who
have relapsed after treatment with prior therapies. The protocol is designed to evaluate two
agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic eff...
Age: 18 years - 66+
Gender: All
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative
rate of participants who receive JNJ-68284528.
Age: 18 years - 66+
Gender: All
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly
diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous
daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confi...
Age: 70 years - 66+
Gender: All
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part
B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination with
BMS-986405 in participants with relapsed and refractory multiple myeloma (MM). The do...
Age: 18 years - 66+
Gender: All
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD)
negativity following the addition of daratumumab to lenalidomide relative to lenalidomide
alone, when administered as maintenance treatment to anti-cluster of differentiation ...
Age: 18 - 79 years
Gender: All
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
This phase II trial studies how well low-dose radiotherapy works in treating bone pain in
patients with multiple myeloma that has spread to the bone. Radiation therapy uses high
energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and s...
Age: 18 years - 66+
Gender: All
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
This study will collect bone marrow (BM) aspirate samples from patients with relapsed
refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the
purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker...
Age: 18 years - 66+
Gender: All